



310 N. Main St., Suite 301  
Chelsea, MI 48118 . USA  
734-433-9670

INTERNATIONAL DISCOVERY SERVICES & CONSULTING

# Pharmacum Nuntius:

December 2012, Volume I, Issue I

For a ten minute coffee break here are a mix of interesting articles spanning fund raising, the world of antibacterial drug discovery, antibodies in cancer research, and on to the latest marked drug for Rheumatoid Arthritis. Enjoy!

Mark Creswell, CEO



## Alternative funding sources for Biotech

Raising capital remains one of the most challenging activates for those of us in the biotech industry. The recently signed JOBS act (Jumpstart Our Business Startup Act) includes provisions which will allow Equity Crowdfunding to move beyond micro investments and donations into the world of Life Science Investing. Our friends at S. Jordon Associates ask the question: "Is Equity Crowd funding a Viable Financing Vehicle for Life Science Companies?" and answer it within a comprehensive 65 page document. This white paper gives you an excellent opportunity to fully learn about Equity Crowdfunding in one location and is available as a [free white paper](#) on their website.

As Angel investors increasingly fill the "Funding gap" a range of Angel portals such as [GUST](#), have become available to the Biotech community. These portals allow companies access to multiple funding groups from one location. Such portals allow one to search for local investors or investors within your chosen field.



## Antibacterials and attrition Management:

IIDSC's Dr. John Domagala is an expert of more than 30 years in the field of Antibacterials. He also led key big-pharma task forces to understand drug discovery and development 'Attrition' and how to critically manage it. In a slide set available on our website, "[Where are the New Antibacterial?](#)" The presentation helps to answers questions like what are the root causes of failure in antibacterial programs and why do these programs have such a different success rate in the clinic when compared to other therapeutic areas?



## Monoclonal Antibodies in Cancer Therapy Review Article:

For those interested in monoclonal antibodies, Andrew Scott, et al have written a very nice review article in Cancer Immunity. The article covers such topics as mechanism of tumor cell killing and FDA approved monoclonal antibodies. It's a quick read and a resource with good references.

<http://cancerimmunity.org/v12p14/>



## New Rheumatoid Arthritis Drug approved by FDA:

Pfizer's new RA drug, Xeljanz<sup>®</sup> (tofacitinib) has been approved:


<http://www.webmd.com/rheumatoid-arthritis/news/20121106/arthritis-drug-xeljanz-fda-approval>



## For more information about IDSC:

Click on our website: [WWW.IDSCBIOTECHNETWORK.COM](http://WWW.IDSCBIOTECHNETWORK.COM)

## A Spotlight on IDSC's Director...David Moreland: Molecular Modeling



Dr. David Moreland has impacted research with a career spanning more than 26 years in big pharma and consulting. With broad expertise in molecular modeling, cheminformatics/QSAR, and structural bioinformatics, he has made key contributions to projects in several therapeutic areas, including CNS, cardiovascular, antiretroviral, and antibacterials. He has successfully applied both ligand-based and structure-based techniques to help teams identify numerous clinical candidates, as exemplified by a phase II compound. He has worked on GPCRs, nuclear hormone receptors, proteases, kinases, and RNA targets. [More...](#)

**FROM HIT TO THE CLINIC: IDSC IS YOUR DRUG DISCOVERY & DEVELOPMENT PARTNER**



[www.idscbiotechnetwork.com](http://www.idscbiotechnetwork.com)